Musculoskeletal Pain - Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026

Musculoskeletal Pain Emerging Therapy and TPP Insights

Thelansis's "Musculoskeletal Pain Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Musculoskeletal Pain Overview

Musculoskeletal pain encompasses a broad range of conditions affecting muscles, joints, bones, and connective tissue, spanning acute injury-related pain to chronic conditions such as osteoarthritis and persistent low back pain, and it remains one of the most common reasons people seek medical care. Historically, more severe cases relied heavily on opioid medications, but growing awareness of risks tied to long-term opioid use has pushed prescribers and drug developers toward non-addictive alternatives, a shift that reached a meaningful milestone with the arrival of a new class of oral pain medicine that blocks pain signals at the peripheral nerve level rather than the brain, offering effectiveness comparable to opioids without their addictive potential. Beyond pharmacologic treatment, management increasingly follows a multimodal approach combining medication with physical therapy, movement-based rehabilitation, and attention to the psychological factors that shape how chronic pain is experienced, reflecting a broader understanding that persistent musculoskeletal pain often involves changes in how the nervous system processes signals rather than ongoing tissue damage alone.

Key Highlights

• In Germany, the prevalent Musculoskeletal Pain population is projected to increase from 12,474,885 in 2025 to 13,112,853 by 2035.
• Musculoskeletal Pain is a leading cause of chronic pain, disability, and reduced quality of life worldwide.
• Current treatment options primarily provide symptomatic relief, with many patients experiencing persistent pain.
• Significant unmet need remains for therapies that provide long-term pain control while improving function and mobility.

Market Overview

• The Spain Musculoskeletal Pain market is projected to grow from $410M in 2025 to $730M by 2035.
• Market growth is driven by:
• Increasing prevalence of chronic musculoskeletal disorders and aging populations
• Growing adoption of novel non-opioid and targeted pain management therapies
• Future growth will depend on the development of safer, more effective long-term treatment options.

Insights driven by surveys with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country